NewFree dose and weight tracker for your phone.Open it →
Amino.Desk

Peptide and GLP-1 dosing chart

Updated Nov 18, 2026 · Clinical review: completed Nov 18, 2026 (details)

Every compound in the library on one page: the approved dose where one exists, and the range people report using. The two columns are not equivalent, and most compounds here have no approved dose at all.

Compound and main usesApproved doseCommunity-reported (not a recommendation)
5-amino-1MQ
Evidence D
Fat loss and "metabolic" support; Holding on to muscle while dieting
NoneOne widely read guide lists 250 to 500 micrograms a day Risks
Adamax
Evidence D
Focus and mental drive
None50 to 150 micrograms a day as a nasal spray, in short runs of about two weeks Risks
Adipotide
Evidence D
Fat loss
None0.5 to 1 mg under the skin once a day, with 0.5 mg described as a common starting amount Risks
AHK-Cu (copper tripeptide)
Evidence D
Thinning hair, in scalp serums; Skin firmness
NoneNo figure we can attribute
AOD-9604
Evidence B
Fat loss; Joint pain, usually alongside other injections
None. Trials used 1 to 30 mg by mouth250 to 500 micrograms under the skin once a day, most often about 300 micrograms Risks
ARA-290 (cibinetide)
Evidence B
Nerve pain from small-fibre neuropathy; Recovery after nerve injury
None approved4 mg under the skin once a day Risks
BPC-157
Evidence C
Tendon, ligament and muscle injuries; Joint pain
None250 to 500 micrograms once or twice a day, injected or by mouth Risks
BPC-157 + KPV blend
Evidence D
Gut complaints and inflammation
NoneNo figure we can attribute
Cagrilintide (and CagriSema)
Evidence B
Obesity, combined with semaglutide as CagriSema; Added to tirzepatide or retatrutide for more weight loss
None approved. Trial target: 2.4 mg a week0.25 mg once a week at the start, stepped up every four weeks toward 2.4 mg a week Risks
CagriSema (cagrilintide + semaglutide)
Evidence B
Obesity and type 2 diabetes; A do-it-yourself version from separate vials
None approved. Trial target: 2.4 mg of each drug a weekUsers source cagrilintide and semaglutide separately and aim for the trial target of 2.4 mg of each once a week Risks
Cartalax
Evidence D
Joint and cartilage complaints
None2 mg a day, in courses of four to eight weeks Risks
Cerebrolysin
Evidence B
Stroke recovery, dementia and brain injury; Sharper thinking in healthy people
None5 to 10 mL injected into muscle Risks
CJC-1295
Evidence C
Raising growth hormone for muscle, fat loss, sleep and recovery
NoneOne widely read guide lists 2 to 4 mg once a week for the DAC version, and 100 to 300 micrograms a day for the version without DAC Risks
CJC-1295 + ipamorelin + tesamorelin blend
Evidence D
Raising growth hormone for fat loss and recovery
NoneNo figure we can attribute
CJC-1295 + ipamorelin blend
Evidence D
Raising growth hormone for muscle, fat loss, sleep and recovery
None100 to 300 micrograms of each, usually at bedtime Risks
Cortagen
Evidence D
Brain and nerve "support"
NoneNo figure we can attribute
Dihexa
Evidence D
Memory, focus and "brain growth"
None5 to 40 mg a day by mouth, or 8 to 12 mg a day under the tongue Risks
DSIP (delta sleep-inducing peptide)
Evidence C
Falling asleep and staying asleep
None100 to 400 micrograms under the skin in the evening, in runs of two to four weeks Risks
Dulaglutide (Trulicity)
Evidence A
Type 2 diabetes; Lowering cardiovascular risk in adults with type 2 diabetes
0.75 mg a week, raised in steps up to 4.5 mgNo figure we can attribute
Eloralintide
Evidence B
Obesity; Weight loss from research vials
None approved. Trial doses are described on this pageNo figure we can attribute
Epitalon
Evidence C
"Anti-ageing" and telomere claims; Sleep and body clock
None5 to 10 mg a day by injection for 10 to 20 days, repeated every four to six months Risks
Epitalon + MOTS-c blend
Evidence D
"Longevity" and energy
NoneNo figure we can attribute
FGL (FG loop peptide)
Evidence C
Memory and thinking
NoneNo figure we can attribute
FOXO4-DRI
Evidence D
Clearing aged "senescent" cells for anti-ageing
None1 to 5 mg every three days, for one to two weeks Risks
GHK-Cu + BPC-157 blend
Evidence D
Skin and injury recovery
NoneNo figure we can attribute
GHK-Cu + KPV blend
Evidence D
Skin and inflammation
NoneNo figure we can attribute
GHK-Cu and the Glow stack
Evidence C
Skin ageing: firmness, texture, fine lines; Scars and wound healing
NoneInjected: 1 to 2 mg a day, or 1 to 2.5 mg two or three times a week Risks
GHRP-2 and GHRP-6
Evidence C
Raising growth hormone for muscle and recovery; Appetite and weight gain, mainly GHRP-6
None100 to 300 micrograms per injection under the skin, up to three times a day Risks
GLOW blend (GHK-Cu + BPC-157 + TB-500)
Evidence D
Skin quality; Injury recovery
None1.4 to 4.2 mg of the blend per injection, which carries 1 to 3 mg of GHK-Cu and 200 to 600 micrograms each of BPC-157 and TB-500 Risks
Glutathione (injectable)
Evidence C
Skin lightening; "Detox" and antioxidant support
None200 to 600 mg by injection, three times a week Risks
Gonadorelin
Evidence C
Keeping testicle function and fertility while on testosterone; Restoring fertility in a rare hormone deficiency, given by pump
None for use alongside testosteroneNo figure we can attribute
Growth hormone (HGH)
Evidence A
Growth hormone deficiency in children and adults, and several named growth and wasting conditions; "Anti-ageing"
Set individually against blood tests0.5 to 4 IU a day by injection Risks
HCG
Evidence A
Triggering ovulation in fertility treatment; Low testosterone caused by a pituitary signalling problem in men
Set by the treating specialist for each approved use150 to 500 IU every other day, alongside testosterone Risks
Hexarelin
Evidence C
Raising growth hormone for muscle and recovery
None100 to 200 micrograms under the skin, two or three times a day Risks
Humanin
Evidence D
"Longevity" and brain protection
None1 to 3 mg of native humanin under the skin two or three times a week, or 100 to 500 micrograms of the stronger HNG version on the same schedule Risks
IGF-1 LR3
Evidence D
Muscle growth
None20 to 80 micrograms a day by injection Risks
Ipamorelin
Evidence C
Raising growth hormone for sleep, recovery and body composition
None100 to 300 micrograms under the skin, usually at bedtime Risks
Khavinson short peptides: Bronchogen, Cardiogen and seven more
Evidence D
"Support" for a named organ: lungs, heart, liver, prostate and so on
NoneNo figure we can attribute
Kisspeptin
Evidence B
Triggering egg maturation in IVF; Low sexual desire
None100 to 500 micrograms of kisspeptin-10, three times a week Risks
KLOW blend (GHK-Cu + BPC-157 + TB-500 + KPV)
Evidence D
Skin quality; Injury recovery and inflammation
None1.6 to 4.8 mg of the blend per injection, which carries 1 to 3 mg of GHK-Cu and 200 to 600 micrograms each of BPC-157, TB-500 and KPV Risks
KPV
Evidence D
Gut inflammation, including inflammatory bowel disease; Inflamed skin, applied as a cream
None200 to 500 micrograms a day Risks
L-carnitine (injectable)
Evidence B
Carnitine deficiency, including in people on dialysis; Weight-loss injections
10 to 20 mg per kilogram into a vein after dialysis. None for weight loss200 to 500 mg a day by injection Risks
Larazotide
Evidence B
Celiac disease; "Leaky gut"
NoneNo figure we can attribute
Lipo-C and Lipo-C + B12 (MIC lipotropic injections)
Evidence D
Weight loss, sold as a "skinny shot"; Energy
NoneNo figure we can attribute
Liraglutide (Saxenda, Victoza)
Evidence A
Long-term weight management; Type 2 diabetes, including lowering cardiovascular risk
Saxenda: 0.6 mg a day, raised weekly to 3 mgNo figure we can attribute
LL-37 (cathelicidin)
Evidence C
Hard-to-heal leg ulcers, applied to the wound; Infections, "biofilms" and immune support, by injection
None100 to 200 micrograms under the skin once a day, often five days on and two off Risks
Mazdutide
Evidence B
Weight management and type 2 diabetes; Weight loss from research vials
None in the US. Trials: 3 to 9 mg a week3 to 9 mg once a week Risks
Melanotan I (afamelanotide, Scenesse)
Evidence A
Erythropoietic protoporphyria, a rare light-sensitivity disorder; Tanning, using injected powder sold as Melanotan I
16 mg implant every two months, placed by a clinician500 to 1,000 micrograms by injection, twice a week Risks
Melanotan II
Evidence C
Tanning; Libido and erections
None250 to 500 micrograms under the skin once a day for one to four weeks, then about 500 micrograms once or twice a week Risks
Methylene blue
Evidence A
Methemoglobinemia, a blood disorder; Memory, focus and energy
1 mg per kilogram into a vein, in hospital. None for other usesAnywhere from 0.5 to 5 mg a few times a week to 5 to 20 mg a day, by mouth Risks
MK-677 (ibutamoren)
Evidence B
Muscle gain; Sleep and appetite
None approved. Trials: 25 mg a day10 to 25 mg a day by mouth Risks
MOTS-c
Evidence D
Fat loss and "metabolic" health; Exercise performance
None5 to 10 mg under the skin two or three times a week Risks
N-acetyl Selank amidate
Evidence D
Anxiety and stress
NoneNo figure we can attribute
N-acetyl Semax amidate
Evidence D
Focus and mental energy
NoneNo figure we can attribute
NAD+
Evidence D
Energy and fatigue, including after illness; "Anti-ageing"
NoneInto muscle: 50 to 200 mg, two or three times a week. Under the skin: 50 to 100 mg. By drip: 500 to 1,000 mg over two to four hours Risks
Oxytocin
Evidence B
Starting or strengthening labour; Social difficulties in autism, as a nasal spray
Hospital drip only. None for the nasal spray10 to 20 IU as a nasal spray, as needed Risks
P21 (P021)
Evidence D
Memory and learning
None100 to 500 micrograms a day Risks
PE-22-28
Evidence D
Low mood
None200 to 400 micrograms a day as a nasal spray, or 100 to 200 micrograms a day by injection Risks
PEG-MGF (mechano growth factor)
Evidence D
Muscle growth and repair
None200 to 400 micrograms per injection, two or three times a week Risks
Pentosan polysulfate (Elmiron)
Evidence A
Bladder pain from interstitial cystitis; Osteoarthritis, as injections
See the label dose belowNo figure we can attribute
Pinealon
Evidence D
Memory, thinking and sleep
None1 to 2 mg a day by injection for 10 to 20 days, or capsules of about 20 mg a day by mouth Risks
PNC-27
Evidence D
Sold online as a cancer treatment
NoneNot published
Progesterone
Evidence A
Protecting the womb lining in women taking estrogen after menopause; Absent periods (secondary amenorrhea)
200 mg at bedtime for 12 days of each cycle, with estrogenNo figure we can attribute
PT-141 (bremelanotide, Vyleesi)
Evidence A
Low sexual desire in premenopausal women; Erectile problems and libido in men
1.75 mg as needed, at most one dose in 24 hours and eight a month1.75 mg under the skin as needed, the same as the label dose Risks
PT-141 + oxytocin blend
Evidence D
Libido and arousal
NoneNo figure we can attribute
Rapamycin (sirolimus)
Evidence B
Preventing kidney transplant rejection; Lymphangioleiomyomatosis, a rare lung disease
Label doses are for transplant and lung disease. Longevity trial: 5 or 10 mg once a weekNo figure we can attribute
Retatrutide
Evidence B
Obesity and weight-related conditions; Type 2 diabetes
None approved. Trials: 2 mg a week, stepped up to 9 or 12 mg0.5 to 12 mg once a week Risks
Retatrutide + cagrilintide blend
Evidence D
Maximum weight loss
NoneUsers start cagrilintide at 0.25 mg a week once retatrutide is established, and step both up over months toward 12 mg of retatrutide and 2.4 mg of cagrilintide a week Risks
Selank
Evidence C
Anxiety; Stress and focus
None250 to 500 micrograms a day as a nasal spray Risks
Semaglutide (Wegovy, Ozempic)
Evidence A
Long-term weight management; Type 2 diabetes
0.25 mg a week, raised in steps to 2.4 mg (injection)Microdosing: 0.1 to 0.25 mg once a week Risks
Semax
Evidence C
Stroke recovery and thinking problems; Focus and mental energy in healthy people
None in the US. Russian clinical practice is described below200 to 600 micrograms as a nasal spray, once or twice a day, in runs of 10 to 14 days Risks
Semax + Selank blend
Evidence D
Focus without anxiety
NoneNo figure we can attribute
Sermorelin
Evidence B
Growth hormone deficiency in children; Sleep, recovery and body composition in adults
None200 to 500 micrograms under the skin at night Risks
SLU-PP-332
Evidence D
Endurance and fat loss, sold as "exercise in a pill"
NoneThere is no agreed figure Risks
SNAP-8 (acetyl octapeptide-3)
Evidence C
Expression lines, in creams and serums
NoneNo figure we can attribute
SS-31 (elamipretide, Forzinity)
Evidence B
Barth syndrome; Fatigue, "mitochondrial support" and exercise performance
40 mg a day, for people 30 kg or heavier1 to 5 mg under the skin once a day is the most common report, within a wider range of 1 to 10 mg Risks
Survodutide
Evidence B
Obesity; MASH, a serious fatty liver disease
None approved. Trials: 3.6 or 6 mg a week after slow steps0.3 to 6 mg once a week, starting low Risks
TB-500
Evidence D
Muscle, tendon and ligament injuries; Recovery after surgery
None2 to 4 mg twice a week Risks
Tesamorelin (Egrifta)
Evidence A
Excess abdominal fat in adults with HIV and lipodystrophy; Fatty liver disease
Once a day; the milligram amount depends on the formulation1 to 2 mg under the skin once a day Risks
Tesamorelin + ipamorelin blend
Evidence D
Belly fat and recovery
NoneNo figure we can attribute
Tesofensine
Evidence B
Weight loss
None approved. Trial doses are described on this pageNo figure we can attribute
Testosterone (cypionate, enanthate)
Evidence A
Low testosterone with an associated medical condition; Age-related low testosterone
Cypionate: 50 to 400 mg every two to four weeksNo figure we can attribute
Thymalin
Evidence C
Immune problems; "Longevity"
None5 to 10 mg a day into muscle for 5 to 10 days, repeated as occasional courses Risks
Thymogen (Glu-Trp)
Evidence C
Immune support
NoneNo figure we can attribute
Thymosin alpha-1
Evidence B
Hepatitis B, and as an immune booster with vaccines; General immune support, chronic infections and fatigue
None in the US. Abroad: 1.6 mg twice a week1.6 mg under the skin twice a week Risks
Thymulin
Evidence D
Immune support
None5 to 10 mg a day for one to two weeks Risks
Tirzepatide (Zepbound, Mounjaro)
Evidence A
Long-term weight management; Type 2 diabetes
2.5 mg a week to start, then 5 to 15 mgMicrodosing: 0.5 to 2 mg once a week Risks
Tirzepatide + BPC-157 blend
Evidence D
Weight loss with fewer stomach side effects
NoneNo figure we can attribute
Vesugen
Evidence D
Blood vessel "support"
NoneNo figure we can attribute
Vilon (Lys-Glu)
Evidence D
Immune support and "anti-ageing"
None100 to 500 micrograms a day under the skin, or one to two capsules a day for 10 to 30 days Risks
VIP (vasoactive intestinal peptide, aviptadil)
Evidence C
Chronic inflammatory illness blamed on mould exposure, as a nasal spray; Brain fog and heat intolerance
None25 to 200 micrograms a day as a nasal spray Risks
Vitamin B12 injections (cyanocobalamin)
Evidence A
B12 deficiency, including pernicious anemia; Energy and weight-loss shots in people who are not deficient
See the label dose belowNo figure we can attribute
Wolverine blend (BPC-157 + TB-500)
Evidence D
Tendon, ligament and muscle injuries; Recovery after surgery or hard training
None250 to 500 micrograms of BPC-157 a day, with 1 to 2.5 mg of TB-500 two or three times a week Risks

This chart is a summary of the library pages as of November 18, 2026. Each compound's own page is the full and current version, with sources. Evidence grades run from A (strong human evidence) to D (little or none) and describe evidence, not safety.

Free field guide

More than ninety peptides, GLP-1s and related compounds: who can legally get what, how strong the evidence is, and what to check before you pay. Plus one short email a week on what changed.

Leave at any time. We do not sell or share your address. Privacy